Skip to content

Ketamine: all studies

Page 438 of 449: studies 4,371 to 4,380 of 4,486, newest first. Back to the ketamine overview

Research

Other Psychoactive Substances

September 4, 2010 G. Hussein Rassool 1 citation

This chapter contains sections titled: LSD (lysergic acid diethylamide) GHB (gammahydroxybutyrate) Ketamine Psilocybin PCP (phencyclidine) Hypnosedatives Volatile substances Over - the - counter drugs Smart and eco drugs References

DOI: 10.1002/9781444327816.ch13 (opens in new tab) Psychoactive substance Traditional medicine Pharmacology Toxicology

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.

Nature Reviews Neuroscience September 2010 Franz X. Vollenweider, Michael Kometer

After a pause of nearly 40 years in research into the effects of psychedelic drugs, recent advances in our understanding of the neurobiology of psychedelics, such as lysergic acid diethylamide (LSD), psilocybin and ketamine have led to renewed interest in the clinical potential of psychedelics in the treatment of various psychiatric disorders. Recent behavioural and neuroimaging data show that...

Glutamatergic Modulators: The Future of Treating Mood Disorders?

Harvard Review of Psychiatry August 1, 2010 Carlos A. Zarate, Rodrigo Machado‐Vieira, Ioline D. Henter et al. 226 citations

Mood disorders such as bipolar disorder and major depressive disorder are common, chronic, and recurrent conditions affecting millions of individuals worldwide. Existing antidepressants and mood stabilizers used to treat these disorders are insufficient for many. Patients continue to have low remission rates, delayed onset of action, residual subsyndromal symptoms, and relapses. New therapeutic...

A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression

Archives of General Psychiatry August 1, 2010 Nancy Diazgranados, Lobna Ibrahim, Nancy E. Brutsché et al. 969 citations

CONTEXT: Existing therapies for bipolar depression have a considerable lag of onset of action. Pharmacological strategies that produce rapid antidepressant effects-for instance, within a few hours or days-would have an enormous impact on patient care and public health. OBJECTIVE: To determine whether an N-methyl-D-aspartate-receptor antagonist produces rapid antidepressant effects in subjects...

Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2).

The International Journal of Neuropsychopharmacology August 1, 2010 Nicolas Tournier, Lucie Chevillard, Bruno Mégarbane et al. 122 citations

Drug interaction with P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) may influence its tissue disposition including blood-brain barrier transport and result in potent drug-drug interactions. The limited data obtained using in-vitro models indicate that methadone, buprenorphine, and cannabinoids may interact with human P-gp; but almost nothing is known about drugs of abuse and...

User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study

Journal of Substance Use July 30, 2010 R. L. Carhart-Harris, D. J. Nutt 108 citations

This study used a web-based questionnaire to investigate user perceptions of the benefits and harms of hallucinogenic drug use. Over 600 forms were submitted. Users were asked to comment on the acute and prolonged effects of different drugs and to provide more specific information on how particular drugs have harmed and/or helped them. Subjects reported relatively less harm associated with the...

The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects.

Psychopharmacology June 1, 2010 Eduardo R Butelman, Szymon Rus, Thomas E Prisinzano et al. 43 citations

The widely available hallucinogen salvinorin A is a unique example of a plant-derived compound selective for kappa-opioid receptors and may produce effects distinct from those of other compounds with classic hallucinogenic or dissociative properties which are also abused in humans. The objective of this study is to characterize the salvinorin A discriminative cue in nonhuman primates with high...

DOI: 10.1007/s00213-009-1771-5 (opens in new tab) Full text (opens in new tab) Salvinorin a Unique hallucinogen Kappa-opioid compound Kappa-opioid receptors +9

NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test.

Journal of Psychopharmacology April 2010 M Ghasemi, M Raza, A R Dehpour

Although there is evidence of the involvement of N-methyl-D-aspartate receptors (NMDAR) in the action of lithium, its role in the antidepressant effects of lithium in a behavioural model remains unclear. In this study, we evaluated the effects of NMDAR antagonists on the antidepressant-like effects of lithium in the mouse forced swimming test. Lithium (30 and 100 mg/kg, i.p.) significantly (P <...

Psychotomimetic effects of PCP, LSD, and Ecstasy: pharmacological models of schizophrenia?

Cambridge University Press eBooks February 4, 2010 Vibeke S. Catts, Stanley V. Catts 12 citations

Facts box Phencyclidine (PCP), ketamine, D-lysergic acid diethylamide (LSD) and 3, 4-methylenedioxy-methamphetamine (MDMA) have been variously referred to as schizophrenomimetics, psychotogens, or psychotomimetics. There have been many reports that these drugs can induce psychotic symptoms (hallucinations, delusions, formal thought disorder, or catatonia-like abnormalities) in the absence of...

Glutamate-based antidepressants: 20 years on.

Trends in pharmacological sciences November 2009 Phil Skolnick, Piotr Popik, Ramon Trullas

Depression is a chronic recurring illness that affects more than 120 million people worldwide. Drugs increasing the synaptic availability of serotonin and norepinephrine (biogenic amine-based agents) have been used to treat depression for more than 50 years. However, significant symptom improvement requires > or =2-4 weeks of treatment and a first course of therapy provides symptom relief to...